Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | PDE5A | O76074 | 2/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23576696 | 1.00 | CYP1A2 (0.33) | CYP1A2CYP3A4CYP2C9CYP2C19THPO | |
| SCHEMBL23600546 | 0.91 | ALOX15 (0.33) | CYP1A2ABCG2PDE5AMAPTSMN1; SMN2 | |
| SCHEMBL29909733 | 0.90 | SLC6A4 (0.34) | ABCG2PDE5AMAPTSMN1; SMN2 | |
| SCHEMBL23577025 | 0.90 | SLC6A4 (0.34) | ABCG2PDE5AMAPTSMN1; SMN2 | |
| SCHEMBL23601182 | 0.89 | PDE5A (0.33) | ABCG2PDE5AMAPTSMN1; SMN2 | |
| SCHEMBL23601201 | 0.88 | GRM5 (0.36) | ABCG2PDE5AMAPTSMN1; SMN2 | |
| SCHEMBL29909000 | 0.87 | CYP1A1 (0.39) | CYP1A2ABCG2PDE5AMAPTSMN1; SMN2 | |
| SCHEMBL23577064 | 0.87 | CYP1A1 (0.39) | CYP1A2ABCG2PDE5AMAPTSMN1; SMN2 | |
| SCHEMBL23576792 | 0.85 | PDPK1 (0.38) | MAPT | |
| SCHEMBL23577272 | 0.84 | ABCG2 (0.32) | ABCG2PDE5AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| EP-4081305-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2022-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | CYP1A2 4595/4885CYP3A4 4334/4885CYP2C9 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.